- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05099809
Registry Trial to Evaluate the Safety and Efficacy of Hyperthermia in Locally Advanced Cancers (RESHMART)
Registry Trial to Evaluate the Safety and Efficacy of Hyperthermia With Radiotherapy and/or Chemotherapy in Locally Advanced Cancers at MGIMS
Mahatma Gandhi Institute of Medical Sciences (MGIMS), Sevagram, District Wardha, Maharashtra, India is located in a rural setup and caters to a very underprivileged patient population with limited resources to even pay for their treatment. As per the latest Indian Cancer Registry Report 2020, of the 28 population based cancer registries (PBCR), the age adjusted incidence rates (AAR) in males and females are 64.9 and 69.9. This makes the AAR in Wardha District (district where MGIMS is located) as one of the lowest ranked AAR both for male (national range: 39.5 - 269.4) and females (national range: 49.4 - 219.8) in the country. However, the %mortality / incidence, is one of the highest for Wardha, both for males (65.9%, national range: 14.7% - 71.9%) and females (53%, national range: 9% - 63%). This indicates that the prognosis of patients in this district is one of the worst in India and thus requires a new approach to their standard therapeutic option. This has to be cost-effective, without any significant additional morbidity, and should used in conjunction to the standard treatment of radiotherapy and/or chemotherapy.
Hyperthermia, which is raising the tumor temperature to 40 - 43°C is perhaps one of the oldest forms of treatment for cancer. Hyperthermia, being a potent radiosensitizer, a chemosensitizer, an immunomodulator with no significantly added side effects, could be an effective therapeutic modality that could be expected to improve the outcome in these patients. However, it also needs to be cost-effective and require low capital cost investment so that other centers, especially in low and low-middle income countries could also introduce hyperthermia to the therapeutic armamentarium for cancer.
This is a registry trial for patients being treated with hyperthermia along with radiotherapy and/or chemotherapy as per the standard departmental protocol for various locally advanced cancers.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
To carry out a registry trial to evaluate the safety and efficacy of hyperthermia delivered by a repurposed short wave diathermy unit working at 27.1 MHz along with radiotherapy and/or chemotherapy in patients with locally advanced tumours of head neck cancers, cancer cervix, breast, oesophagus and anorectum attending the department of radiotherapy, MGIMS.
This would help to create an organized system that uses observational methods to collect uniform data on safety and efficacy of hyperthermia when used in conjunction with standard therapeutic modalities of radiotherapy and/or chemotherapy. The study would help to,
i. Evaluate the specific outcomes with hyperthermia in terms of the following clinical endpoints with hyperthermia
- Locoregional tumour control
- Local disease free survival
- Overall survival
ii. Evaluate the safety of hyperthermia along with standard therapeutic modalities of radiotherapy and/or chemotherapy
- Acute morbidity
- Late morbidity
iii. Evaluate the feasibility of carrying out hyperthermia by repurposing 27.12 MHz short wave diathermy unit that could be cost-effective
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Niloy R Datta, MD, DNB, CCST
- Phone Number: +91-9717388117
- Email: niloydatta@mgims.ac.in
Study Contact Backup
- Name: Bharati M Jain, PhD
- Phone Number: +91-9921590897
- Email: bharati@mgims.ac.in
Study Locations
-
-
Maharashtra
-
Sevagram, Maharashtra, India, 442101
- Recruiting
- Mahatma Gandhi Institute of Medical Sciences
-
Contact:
- Niloy R Datta, MD, DNB, CCST
- Phone Number: +91-9717388117
- Email: niloydatta@mgims.ac.in
-
Contact:
- Bharati M Jain, PhD
- Phone Number: +91-9921590897
- Email: bharati@mgims.ac.in
-
Sevagram, Maharashtra, India, 442102
- Recruiting
- Mahatma Gandhi Institute of Medical Sciences,
-
Contact:
- Niloy R Datta, MD, DNB
- Phone Number: +919717388117
- Email: niloydatta@magims.ac.in
-
Contact:
- Bharati M Jain, PhD
- Phone Number: +919921590897
- Email: bharati@mgims.ac.in
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Histopathologically proven cases of locally advanced head and neck cancers (LAHNC), TNM stages III and IV and locally advanced cancer cervix (LACC), FIGO stages IIB - IVA, locally advanced (primarily inoperable T3 and T4 stages) and recurrent breast cancers, cancer oesophagus (TNM stages IIA and IVA), anorectal cancers (TNM stages IIA to IIIC)
- Following work up, patients should have no metastatic disease (M0)
- Age > 18 years
- Karnofsky performance status (KPS) ≥ 80
- Written informed consent and agree to comply with the protocol
- Adequate kidney and liver functions as assessed on biochemical investigations
- Absence of psychological, familial, sociological or geographical condition that could potentially hamper compliance with the study protocol and follow-up schedule
Exclusion Criteria:
- Prior radiotherapy to the site of treatment
- No prior or concurrent malignancies other than surgically treated squamous cell or basal cell carcinoma of the skin which are not in the area of the present malignancy
- Psychiatric or addictive disorders or other conditions that, in the opinion of the investigator would preclude the patient from meeting the study requirements.
- Patients having metal implants, pacemakers or clustered markers.
- Connective disease disorders that contraindicate radiotherapy, e.g., Scleroderma
- Any known contraindication or hypersensitivity to the chemotherapeutic agents
- Pregnancy, lactation period or lack of reliable contraception
- Any other disease or therapy, which, according to the investigator, present a risk to the patient or which are not compatible with the aims of the clinical trial
- Indications that the person concerned will possibly not keep to the clinical trial plan because of unwillingness to cooperate or difficulties in keeping the check-up appointments
- Breast feeding female patients
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Hyperthermia
Patients with locally advanced cancers reporting to Department of Radiotherapy at MGIMS who fulfil the eligibility criteria would be included in the study. Depending on the ongoing departmental protocols for various tumors the patients could be treated with either:
Tumour response would be evaluated using RECIST criteria 1.1 while the acute and late morbidities would be scored as per CTCAE v5.0 guidelines. Outcome measures for each site would be undertaken and evaluated in terms of
|
Hyperthermia would be delivered once/twice a week for 60 to 90 minutes depending on patient's tolerance.
A shortwave diathermy unit operating at 27.1 MHz would be used to deliver locoregional hyperthermia.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Locoregional tumour control
Time Frame: At 3 months after the completion of primary treatment
|
Locoregional control of the tumour
|
At 3 months after the completion of primary treatment
|
Disease free survival
Time Frame: Through study completion, an average of 1 year
|
From date of registration until the date of first documented progression or date of death from any cause, whichever came first, assessed till end of the study completion, an average of 1 year
|
Through study completion, an average of 1 year
|
Overall survival
Time Frame: Through study completion, an average of 1 year
|
From date of registration until the date of death from any cause, assessed till end of the study completion, an average of 1 year
|
Through study completion, an average of 1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Acute treatment related morbidity
Time Frame: Till 3 months following the completion of primary treatment
|
Acute treatment morbidity as per CTCAE 5.0 guidelines
|
Till 3 months following the completion of primary treatment
|
Late treatment related morbidity
Time Frame: Through study completion, an average of 1 year
|
Late treatment morbidity as per CTCAE 5.0 guidelines
|
Through study completion, an average of 1 year
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MahatmaIGMS
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- Study Protocol
- Statistical Analysis Plan (SAP)
- Informed Consent Form (ICF)
- Clinical Study Report (CSR)
- Analytic Code
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Locally Advanced Malignant Neoplasm
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)CompletedAdvanced Malignant Neoplasm | Locally Advanced Malignant NeoplasmUnited States
-
University of California, San FranciscoCompletedIntegrative Palliative Care/Psycho-Oncology Telehealth Intervention in Patients With Advanced CancerAdvanced Malignant Solid Neoplasm | Locally Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid NeoplasmUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingLocally Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid NeoplasmUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingMetastatic Malignant Neoplasm | Caregiver | Advanced Malignant Neoplasm | Locally Advanced Malignant NeoplasmUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingLocally Advanced Malignant Solid NeoplasmUnited States
-
National Cancer Institute (NCI)RecruitingLocally Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid NeoplasmUnited States, Puerto Rico
-
M.D. Anderson Cancer CenterTerminatedLocally Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid NeoplasmUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingMalignant Neoplasm | Metastatic Malignant Neoplasm | Advanced Malignant Neoplasm | Recurrent Malignant Neoplasm | Locally Advanced Malignant NeoplasmUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingMetastatic Malignant Neoplasm | Advanced Malignant Neoplasm | Recurrent Malignant Neoplasm | Refractory Malignant Neoplasm | Locally Advanced Malignant NeoplasmUnited States
-
M.D. Anderson Cancer CenterNot yet recruitingHematopoietic and Lymphoid Cell Neoplasm | Advanced Malignant Solid Neoplasm | Locally Advanced Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid NeoplasmUnited States
Clinical Trials on Hyperthermia
-
Roswell Park Cancer InstituteCompletedMelanoma | Soft Tissue Sarcoma | Breast Carcinoma | Lung Carcinoma | Malignant Neoplasm | Colon Carcinoma | Ovarian Neoplasm | Malignant Head and Neck Neoplasm | Adult Liver Carcinoma | Kidney NeoplasmUnited States
-
University of ZurichRecruiting
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Active, not recruitingRecurrent Prostate CarcinomaUnited States
-
Mark DewhirstWithdrawn
-
Fachklinik Hornheide an der Universität MünsterUnknownAdvanced Metastastic Malignant Melanoma | Refractory to First-Line Chemotherapy Irresectable Progressive Soft Tissue MetastasesGermany
-
Maria Sklodowska-Curie National Research Institute...Completed
-
University of Erlangen-Nürnberg Medical SchoolUnknown
-
Kantonsspital Winterthur KSWLuzerner KantonsspitalNot yet recruitingBasal Cell Carcinoma | Non-melanoma Skin Cancer | Squamous Cell Carcinoma SkinSwitzerland
-
Kantonsspital AarauUniversity Hospital, Zürich; Center for Proton Therapy, Paul Scherrer Institute...UnknownSoft Tissue SarcomaSwitzerland